Search

Displaying results 3571 - 3580 of 10000 in total
  1. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  2. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Cetrorelix

    go.drugbank.com/drugs/DB00050
    ApprovedInvestigational

    Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). … GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle.

    Products: CETROTIDE® 0.25MG, CETROTIDE 3 MG.
  4. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravarine must always be used in combination with other antiretroviral drugs. … of rashes in patients taking etravirine, lead to a modification of etravirine's monograph.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: INTELENCE®TABLETAS 200MG
  5. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    [L28001] As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation in highly sensitized patients to proceed.[A225836,L28001] … Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large.

  6. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961. … It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.

    Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamideProducts: XELTETRA-L, TETRALYSAL® CAPSULAS 300 MG
  7. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK. … GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline

  8. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

  9. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

    Categories: MATE 1 Substrates, MATE 2 Inhibitors
  10. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L40026] It received subsequent approval for the same indications in Canada in May 2022. … efficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy.